|
注册号: Registration number: |
ChiCTR1800020440 |
|
最近更新日期: Date of Last Refreshed on: |
2018-12-29 20:45:46 |
|
注册时间: Date of Registration: |
2018-12-29 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
炎症标志物与关节置换术后假体周围感染治疗有效性的相关性分析 |
|
Public title: |
Analysis for correlation between inflammatory markers and effectiveness of treatment for periprosthetic infection after joint replacement |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
炎症标志物与关节置换术后假体周围感染治疗有效性的相关性分析 |
|
Scientific title: |
Analysis for correlation between inflammatory markers and effectiveness of treatment for periprosthetic infection after joint replacement |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
杨建业 |
研究负责人: |
胡宁 |
|
Applicant: |
Jianye Yang |
Study leader: |
Ning Hu |
|
申请注册联系人电话: Applicant telephone: |
+86 13038355869 |
研究负责人电话:
Study leader's |
+86 18696761022 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
842503700@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
HuNjoint@yahoo.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
重庆市渝中区袁家岗友谊路1号 |
研究负责人通讯地址: |
重庆市渝中区袁家岗友谊路1号 |
|
Applicant address: |
1 Youyi Road, Yuzhong District, Chongqing, China |
Study leader's address: |
1 Youyi Road, Yuzhong District, Chongqing, China |
|
申请注册联系人邮政编码: Applicant postcode: |
400016 |
研究负责人邮政编码: Study leader's postcode: |
400016 |
|
申请人所在单位: |
重庆医科大学附属第一医院 |
||
|
Applicant's institution: |
First Affiliated Hospital of Chongqing Medical University |
||
|
研究负责人所在单位: |
重庆医科大学附属第一医院 |
||
|
Affiliation of the Leader: |
First Affiliated Hospital of Chongqing Medical University |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
20187101 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
重庆医科大学附属第一医院药物临床试验伦理委员会 |
||
|
Name of the ethic committee: |
The Ethics Committee of Drug Clinical Trials of the First Affiliated Hospital of Chongqing Medical University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2018-09-26 00:00:00 | ||
|
伦理委员会联系人: |
罗天友 |
||
|
Contact Name of the ethic committee: |
Tianyou Luo |
||
|
伦理委员会联系地址: |
重庆市渝中区友谊路1号 重庆医科大学附属第一医院 |
||
|
Contact Address of the ethic committee: |
The First Affiliated Hospital of Chongqing Medical University, 1 Youyi Road, Yuzhong District, Chongqing, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
||
|
研究实施负责(组长)单位: |
重庆医科大学附属第一医院 |
||||||||||||||||||||||
|
Primary sponsor: |
The First Affiliated Hospital of Chongqing Medical University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
重庆市渝中区友谊路1号 重庆医科大学附属第一医院 |
||||||||||||||||||||||
|
Primary sponsor's address: |
1 Youyi Road, Yuzhong District, Chongqing, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
研究生经费 |
||||||||||||||||||||||
|
Source(s) of funding: |
funds for postgraduates |
||||||||||||||||||||||
|
研究疾病: |
假体周围感染 |
||||||||||||||||||||||
|
Target disease: |
periprosthetic joint infection |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
病因学/相关因素研究 |
||||||||||||||||||||||
|
Study type: |
Cause/Relative factors study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
单臂 |
||||||||||||||||||||||
|
Study design: |
Single arm |
||||||||||||||||||||||
|
研究目的: |
通过对假体周围感染行手术治疗后的长期随访,随访内容主要为相关炎症标志物:血常规、ESR、CRP、IL-6、PCT、凝血象、a-防御素等进行控制性的抗生素治疗,以随访记录的模式进行疗效的评估,以期达到疾病的诊断及治疗有效性的评估。 |
||||||||||||||||||||||
|
Objectives of Study: |
Long-term follow-up after surgical treatment of infection around the prosthesis, follow-up content is mainly related to inflammation markers: blood routine, ESR, CRP, IL-6, PCT, coagulation, a-defensin, etc. for controlled antibiotic treatment Efficacy assessment was performed in a follow-up recording model to achieve diagnosis of the disease and assessment of the effectiveness of the treatment. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||
|
排除标准: |
1)未在我科行关节置换术后假体周围感染治疗的患者; |
||||||||||||||||||||||
|
Exclusion criteria: |
1) Patients who have not been treated for infection around the prosthesis after joint replacement in our department; |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2019-01-01 00:00:00至 To 2023-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2019-01-01 00:00:00 至 To 2023-01-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无需随机 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
N/A |
|
Blinding: |
N/A |
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
提供病例记录表查阅 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
we provide of case record form to review |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
病例记录表和医院电子病历系统 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Case Record Form and the hospital's electronic record system |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |